The C-terminal fragment of big endothelin-1 does not potentiate the vasoactive effects of endothelin-1

Clinical Physiology

Volumn 18, Issue 1, 1998, Pages 61-68

  Ottosson Seeberger, A ^a   Hemsen A ^b   Lundberg, J M ^b   Ahlborgt, G ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Blood pressure; Cardiac output; Cerebral blood flow; Forearm blood flow; Heart rate; Renal blood flow; Splanchnic blood flow; Vascular resistance

Indexed keywords

ENDOTHELIN 1;

ADULT; ARTICLE; BRAIN BLOOD FLOW; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; FOREARM BLOOD FLOW; HEART OUTPUT; HEART RATE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; LUNG ARTERY PRESSURE; LUNG CAPILLARY PRESSURE; LUNG PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; PRIORITY JOURNAL; SPLANCHNIC BLOOD FLOW; SYSTEMIC VASCULAR RESISTANCE;

ADULT; BLOOD PRESSURE; CATECHOLAMINES; CEREBROVASCULAR CIRCULATION; DRUG SYNERGISM; ENDOTHELIN-1; ENDOTHELINS; HEMODYNAMIC PROCESSES; HUMANS; MALE; MUSCLE, SKELETAL; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; PULMONARY CIRCULATION; RENAL CIRCULATION; SPLANCHNIC CIRCULATION; TIME FACTORS;

EID: 0031929674     PISSN: 01445979     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2281.1998.00074.x     Document Type: Article

References (19)

1. AHLBORG G., OTTOSSON-SEEBERGER A., HEMSÉN A. & LUNDBERG J. M. (1994) Big ET-1 infusion in man causes renal ET-1 release, renal and splanchnic vasoconstriction, and increased mean arterial blood pressure. Cardiovasc Res, 28, 1559-1563.
2. AHLBORG G., WEITZBERG E. & LUNDBERG J. M. (1995) Circulating endothelin-1 reduces splanchnic and renal blood flow and splanchnic glucose production in humans. J Appl Physiol, 79, 141-145.
3. AHLBORG G., OTTOSSON-SEEBERGER A., HEMSÉN A. & LUNDBERG J. M. (1996) Central and regional hemodynamic effects during infusion of big endothelin-1 in healthy humans. J Appl Pbysiol, 80, 1921-1927.
4. BRUN A. (1951) A rapid method for the determination of paraaminohippuric acid in kidney function tests. J Lab Clin Med, 37, 955-958.
5. D'ORLÉANS-JUSTE P., LlDBURY P. S., WARNER T. D. & VANE J. R. (1990) Intravascular big endothelin increases circulating levels of endothelin-1 and prostanoids in the rabbit. Biocbem Pharmacol, 39, R21-R22.
6. FUKURODA T., NOGUCHI K., TSUCHIDA S., NISHIKIBE M., IKEMOTO F., OKADA K. & YANO M. (1990) Inhibition of biological actions of big endothelin-1 by phosphoramidon. Biochem Biophys Res Commun, 172, 390-395.
7. GRAF K. & WESTERSTEN A. (1959) Untersuchungen über Eigenschaften und Verwendungsmöglichkeiten eines flexiblen Extremitätenplethysmografen. Acta Physiol Scand, 46, 1-18.
8. HEMSÉN A., PERNOW J. & LUNDBERG J. M. (1991a) Regional extraction of endothelins and conversion of big endothelin to endothelin-1 in the pig. Acta Physiol Scand, 141, 325-334.
9. HEMSÉN A., LARSSON O. & LUNDBERG J. M. (1991b) Characteristics of endothelin A and B binding sites and their vascular effects in pig peripheral tissues. Eur J Pharmacol, 208, 313-322.
10. HEMSÉN A., AHLBORG G., OTTOSSON-SEEBERGER A. & LUNDBERG J. M. (1995) Metabolism of big endothelin-1 (1-38) and (22-38) in the human circulation in relation to production of endothelin-1 (1-21). Regul Pept, 55, 287-297.
11. HJEMDAHL P. (1987) Catecholamine measurements in plasma by high-performance liquid chromatography with electrochemical detection. Methods Enzymol, 142, 521-534.
12. JOHANSSON B. L., LINDE B. & WAHREN J. (1992) Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 (insulin-dependent) diabetic patients. Diabetologia, 35, 1151-1158.
13. KASHIWABARA T., INAGAKI Y., OHTA H., IWAMATSU A., NOMIZU M., MORITA A. & NISHIKORI K. (1989) Putative precursors of endothelin have less vasoconstrictor activity in vitro but a potent pressor effect in vivo. FEBS Lett, 247, 73-76.
14. MATSUMURA Y., HISAKI K., TAKAOKA M. & MORIMOTO S. (1990) Phosphoramidon, a metalloprotease inhibitor, suppresses the hypertensive effect of big endothelin-1. Eur J Pharmacol, 185, 103-106.
15. ROWELL L. B., BLACKMON J. R. & BRUCE R. A. (1964) Indocyanine green clearance and estimated hepatic blood flow during mild to maximal exercise in upright man. 7 Clin Invest, 43, 1677-1690.
16. WEITZBERG E., AHLBORG G. & LUNDBERG J. M. (1991) Long-lasting vasoconstriction and efficient regional extraction of endothelin-1 in human splanchnic and renal tissues. Biochem Biophys Res Commun, 180, 1298-1303.
17. WEITZBERG E., AHLBORG G. & LUNDBERG J. M. (1993) Differences in vascular effects and removal of endothelin-1 in human lung, brain, and skeletal muscle. Clin Physiol, 13, 653-662.
18. WORLD MEDICAL ASSOCIATION. (1964) Human experimentation. Code of ethics of the World Medical Association: Declaration of Helsinki. Br Med J, 2, 177.
19. YANAGISAWA M., KURIHARA H., KIMURA S., TOMOBE Y., KOBAYASHI M., MITSUI Y., YAZAKI Y., GOTO K. & MASAKI T. (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 332, 411-415.